My research over the years has given a Sales/Price ratio of 15 times for purchases of Biopharma products. The purchaser rarely wants to buy higher than 15 times. I’m not talking about a takeover, this is for the sale of the product Daybue to commercialise. If anyone wants to weigh in on this… please do.
Daybue Pricing, page-23
Add NEU (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$19.36 |
Change
-0.500(2.52%) |
Mkt cap ! $2.494B | |||
| Open | High | Low | Value | Volume |
| $19.70 | $19.77 | $19.33 | $5.570M | 285.9K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 2 | 33 | $19.35 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $19.36 | 9 | 3 |
View Market Depth
| Last trade - 11.08am 30/07/2024 (20 minute delay) ? |
| NEU (ASX) Chart |